Salatan, Janese A.
HRN: 23-13-85 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/29/2023
CEFUROXIME 500MG (TAB)
06/29/2023
07/05/2023
PO
500mg
BID
S/P LSCS
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueIntra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes